Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T13714 | ||||
Target Name | Oxysterols receptor LXR-beta | ||||
Target Type | Research |
||||
Drug Potency against Target | GSK-9772 | Drug Info | IC50 = 30 nM | [529702] | |
17-dehydroxyriccardin C | Drug Info | IC50 = 13000 nM | [529375] | ||
WAY-214950 | Drug Info | IC50 = 33 nM | [529781] | ||
4,17-dehydroxyriccardin C | Drug Info | IC50 = 7300 nM | [529375] | ||
12,17-dehydroxyriccardin C | Drug Info | IC50 = 14000 nM | [529375] | ||
Riccardin C | Drug Info | IC50 = 6600 nM | [529375] | ||
GW-3965 | Drug Info | IC50 = 12 nM | [529781] | ||
WAY-252623 | Drug Info | IC50 = 24 nM | [529781] | ||
2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole | Drug Info | IC50 = 41 nM | [529781] | ||
12-dehydroxyriccardin C | Drug Info | IC50 = 7600 nM | [529375] | ||
4-dehydroxyriccardin C | Drug Info | IC50 = 10000 nM | [529375] | ||
References | |||||
Ref 529702 | J Med Chem. 2008 Sep 25;51(18):5758-65.Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. | ||||
Ref 529375 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
Ref 529781 | J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. | ||||
Ref 529375 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
Ref 529375 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
Ref 529375 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
Ref 529781 | J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. | ||||
Ref 529781 | J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. | ||||
Ref 529781 | J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. | ||||
Ref 529375 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. | ||||
Ref 529375 | Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. Epub 2008 Feb 29.Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.